Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin Meeting Abstract

  

Authors:	Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; Casper, E.; Galasso, N.; Subzwari, S.; Jihad, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Kumar, A.; Lue, J. K.; Luttwak, E.; Noy, A.; Owens, C.; Palomba, M. L.; Salles, G.; Steiner, R.; Stuver, R.; Torka, P.; Vardhana, S. A.; Zelenetz, A. D.; Yahalom, J.; Dogan, A.; Schoder, H.; Moskowitz, C. H.
Abstract Title:	Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
Meeting Title:	66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	144
Issue:	Suppl. 1
Meeting Dates:	2024 Dec 7-10
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-05
Start Page:	569
End Page:	570
Language:	English
ACCESSION:	WOS:001414815800019
DOI:	10.1182/blood-2024-202537
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/226865